anurajms/meta_analysis huggingface dataset:
MESH terms:
Skin care interventions in infants for preventing eczema and food allergy
1. Allergens [therapeutic use]; 2. Cattle; 3. *Eczema [drug therapy, prevention & control]; 4. Emollients [therapeutic use]; 5. *Food Hypersensitivity [prevention & control]; 6. *Milk Hypersensitivity;
MESH terms:
Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
1. Antifungal Agents [therapeutic use]; 2. *Aspergillosis, Allergic Bronchopulmonary [complications, drug therapy]; 3. Aspergillus fumigatus; 4. *Cystic Fibrosis [complications, drug therapy]; 5. Itraconazole [therapeutic use];
MESH terms:
Anti‐IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
1. Antibodies, Anti-Idiotypic; 2. Antifungal Agents [therapeutic use]; 3. *Aspergillosis, Allergic Bronchopulmonary [drug therapy]; 4. *Cystic Fibrosis [complications, drug therapy]; 5. Prospective Studies; 6. Randomized Controlled Trials as Topic;
MESH terms:
Whole‐cell pertussis vaccine in early infancy for the prevention of allergy in children
1. Bias; 2. *Eczema; 3. *Hypersensitivity, Immediate; 4. Pertussis Vaccine [adverse effects]; 5. *Whooping Cough;
MESH terms:
High versus low medium chain triglyceride content of formula for promoting short‐term growth of preterm infants
1. Bias; 2. Body Height; 3. Dietary Fats [adverse effects, *analysis]; 4. Head [growth & development]; 5. Infant Food [adverse effects, *analysis]; 6. Infant Nutritional Physiological Phenomena; 7. Infant, Low Birth Weight [*growth & development]; 8. Infant, Premature [growth & development]; 9. Randomized Controlled Trials as Topic; 10. Triglycerides [adverse effects, *analysis, chemistry]; 11. Weight Gain;
MESH terms:
Sublingual immunotherapy for asthma
1. Asthma [*therapy]; 2. Disease Progression; 3. Hospitalization [statistics & numerical data]; 4. Placebos [therapeutic use]; 5. Pollen; 6. Pyroglyphidae; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Rhinitis, Allergic [therapy]; 10. Sublingual Immunotherapy [adverse effects, *methods];
MESH terms:
Dilute versus full‐strength formula in exclusively formula‐fed preterm or low birth weight infants
1. Energy Intake; 2. *Enterocolitis, Necrotizing [epidemiology, prevention & control]; 3. *Infant Formula; 4. *Infant Nutritional Physiological Phenomena; 5. *Infant, Low Birth Weight; 6. *Infant, Premature; 7. Length of Stay; 8. Weight Gain;
MESH terms:
Probiotics for treating eczema
1. Eczema [*therapy]; 2. Probiotics [*therapeutic use]; 3. Randomized Controlled Trials as Topic; 4. Symptom Assessment; 5. Treatment Outcome;
MESH terms:
Infant formulas containing hydrolysed protein for prevention of allergic disease
1. *Dietary Proteins; 2. Asthma [epidemiology]; 3. Breast Feeding; 4. Dermatitis, Atopic [epidemiology]; 5. Food Hypersensitivity [*prevention & control]; 6. Infant Formula [*chemistry]; 7. Milk; 8. Milk Hypersensitivity [prevention & control]; 9. Milk, Human; 10. Protein Hydrolysates [*administration & dosage]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Oral and sublingual immunotherapy for egg allergy
1. Administration, Oral; 2. Desensitization, Immunologic [adverse effects, *methods]; 3. Egg Hypersensitivity [*therapy]; 4. Egg Proteins, Dietary [*administration & dosage, immunology]; 5. Epinephrine [therapeutic use]; 6. Immunoglobulin E [immunology]; 7. Randomized Controlled Trials as Topic; 8. Sublingual Immunotherapy [adverse effects, methods];
MESH terms:
Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy
1. *Dietary Supplements; 2. Asthma [prevention & control]; 3. Dermatitis [prevention & control]; 4. Fatty Acids, Unsaturated [*administration & dosage]; 5. Food Hypersensitivity [prevention & control]; 6. Hypersensitivity [epidemiology, *prevention & control]; 7. Prevalence; 8. Randomized Controlled Trials as Topic; 9. Rhinitis, Allergic [epidemiology, prevention & control];
MESH terms:
Specific allergen immunotherapy for the treatment of atopic eczema
1. Allergens [*therapeutic use]; 2. Dermatitis, Atopic [*therapy]; 3. Dermatophagoides farinae; 4. Dermatophagoides pteronyssinus; 5. Desensitization, Immunologic [*methods]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion
1. *Leukocyte Reduction Procedures; 2. Cause of Death; 3. Erythrocyte Transfusion [*adverse effects]; 4. Infections [etiology]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Immunotherapy (oral and sublingual) for food allergy to fruits
1. Desensitization, Immunologic [*methods]; 2. Food Hypersensitivity [etiology, *therapy]; 3. Fruit [*adverse effects]; 4. Malus [*adverse effects]; 5. Pyrus [*adverse effects]; 6. Randomized Controlled Trials as Topic; 7. Sublingual Immunotherapy [methods];
MESH terms:
Glycerin laxatives for prevention or treatment of feeding intolerance in very low birth weight infants
1. *Infant, Very Low Birth Weight; 2. Enema [methods]; 3. Enteral Nutrition [*adverse effects]; 4. Gestational Age; 5. Glycerol [*therapeutic use]; 6. Laxatives [*therapeutic use]; 7. Meconium; 8. Randomized Controlled Trials as Topic; 9. Suppositories;
MESH terms:
Maternal prenatal and/or postnatal n‐3 long chain polyunsaturated fatty acids (LCPUFA) supplementation for preventing allergies in early childhood
1. *Dietary Supplements; 2. Age Factors; 3. Fatty Acids, Omega‐3 [*administration & dosage]; 4. Food Hypersensitivity [prevention & control]; 5. Hypersensitivity [*prevention & control]; 6. Immunoglobulin E [immunology]; 7. Postnatal Care; 8. Prenatal Care; 9. Randomized Controlled Trials as Topic;
MESH terms:
H1‐antihistamines for chronic spontaneous urticaria
1. Cetirizine [therapeutic use]; 2. Cyproheptadine [analogs & derivatives, therapeutic use]; 3. Histamine H1 Antagonists [adverse effects, *therapeutic use]; 4. Hydroxyzine [therapeutic use]; 5. Loratadine [analogs & derivatives, therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Urticaria [*drug therapy];
MESH terms:
Omalizumab for asthma in adults and children
1. Adrenal Cortex Hormones [therapeutic use]; 2. Anti‐Asthmatic Agents [administration & dosage, *therapeutic use]; 3. Antibodies, Anti‐Idiotypic [administration & dosage, *therapeutic use]; 4. Antibodies, Monoclonal, Humanized [administration & dosage, *therapeutic use]; 5. Asthma [*drug therapy, immunology]; 6. Chronic Disease; 7. Immunoglobulin E [blood, *immunology]; 8. Injections, Subcutaneous; 9. Omalizumab; 10. Randomized Controlled Trials as Topic;
MESH terms:
Prebiotics in infants for prevention of allergy
1. *Infant Formula; 2. *Prebiotics; 3. Asthma [prevention & control]; 4. Eczema [prevention & control]; 5. Food Hypersensitivity [prevention & control]; 6. Hypersensitivity [*prevention & control]; 7. Milk Hypersensitivity [prevention & control]; 8. Oligosaccharides [*therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Urticaria [prevention & control];
MESH terms:
Lactase treated feeds to promote growth and feeding tolerance in preterm infants
1. *Enteral Nutrition; 2. *Parenteral Nutrition; 3. Infant Nutritional Physiological Phenomena; 4. Infant, Premature [*growth & development]; 5. Lactase [*therapeutic use]; 6. Lactose Intolerance [prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Weight Gain;
MESH terms:
Oral H1 antihistamines as monotherapy for eczema
1. Administration, Oral; 2. Eczema [*drug therapy]; 3. Histamine H1 Antagonists [*administration & dosage];
MESH terms:
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta thalassaemia
1. Amlodipine [adverse effects]; 2. *beta-Thalassemia [complications, drug therapy]; 3. Calcium Channel Blockers [adverse effects]; 4. *Cardiomyopathies [etiology, prevention & control]; 5. Edema; 6. Ferritins; 7. Iron [therapeutic use]; 8. Iron Chelating Agents [adverse effects]; 9. *Iron Overload [complications, drug therapy, prevention & control];
MESH terms:
Topical repellents for malaria prevention
1. Controlled Before-After Studies; 2. *Culicidae; 3. *Insecticides; 4. *Malaria, Falciparum; 5. Mosquito Vectors;
MESH terms:
Interventions for chronic kidney disease in people with sickle cell disease
1. *Acute Chest Syndrome [chemically induced, complications, drug therapy]; 2. *Anemia, Sickle Cell [complications]; 3. Angiotensin-Converting Enzyme Inhibitors [therapeutic use]; 4. Antisickling Agents [therapeutic use]; 5. Ascorbic Acid [therapeutic use]; 6. Captopril [therapeutic use]; 7. Creatinine; 8. Hydroxyurea [therapeutic use]; 9. *Kidney Failure, Chronic; 10. Lisinopril [therapeutic use]; 11. Proteinuria [etiology];
MESH terms:
Rapamycin and rapalogs for tuberous sclerosis complex
1. *Angiofibroma; 2. *Angiomyolipoma; 3. *Astrocytoma [drug therapy]; 4. Everolimus [adverse effects]; 5. *Kidney Neoplasms [drug therapy]; 6. MTOR Inhibitors; 7. Sirolimus [adverse effects]; 8. *Tuberous Sclerosis [complications, drug therapy];
MESH terms:
Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults
1. Antilymphocyte Serum [therapeutic use]; 2. Bone Marrow Transplantation; 3. *Bronchiolitis Obliterans Syndrome; 4. *Graft vs Host Disease [prevention & control]; 5. *Hematopoietic Stem Cell Transplantation [adverse effects];
MESH terms:
Treatment for osteoporosis in people with beta‐thalassaemia
1. Alendronate; 2. *beta-Thalassemia [complications, drug therapy]; 3. Clodronic Acid; 4. Denosumab [therapeutic use]; 5. Diphosphonates [therapeutic use]; 6. *Fractures, Bone; 7. *Osteoporosis [drug therapy, etiology]; 8. Pamidronate;
MESH terms:
Treatment of dental and orthodontic complications in thalassaemia
1. *Gingivitis; 2. *Thalassemia [complications, therapy];
MESH terms:
Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias
1. *beta-Thalassemia [therapy]; 2. Blood Transfusion; 3. Fetal Hemoglobin; 4. Hydroxyurea; 5. Resveratrol;
MESH terms:
Laser therapy for retinopathy in sickle cell disease
1. *Anemia, Sickle Cell [complications]; 2. *Choroidal Neovascularization [etiology]; 3. Intravitreal Injections; 4. *Laser Therapy [adverse effects]; 5. Quality of Life; 6. Vision Disorders;
MESH terms:
Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease
1. *Acute Chest Syndrome [drug therapy, etiology]; 2. *Anemia, Sickle Cell [complications, drug therapy]; 3. *Asthma; 4. Bronchi; 5. Bronchodilator Agents [therapeutic use];
MESH terms:
Extracorporeal photopheresis versus standard treatment for acute graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents
1. Adrenal Cortex Hormones; 2. *Graft vs Host Disease [therapy]; 3. *Hematopoietic Stem Cell Transplantation [adverse effects]; 4. Methoxsalen [therapeutic use]; 5. *Photopheresis [methods]; 6. Steroids;
MESH terms:
Hydroxyurea (hydroxycarbamide) for sickle cell disease
1. *Acute Chest Syndrome [chemically induced, complications, drug therapy]; 2. *Anemia, Sickle Cell [complications, drug therapy]; 3. Antisickling Agents [adverse effects]; 4. Hemoglobin, Sickle [therapeutic use]; 5. Hydroxyurea [adverse effects]; 6. Pain [drug therapy]; 7. *Stroke [prevention & control];
MESH terms:
Inhaled nitric oxide for treating pain crises in people with sickle cell disease
1. Analgesics [therapeutic use]; 2. *Anemia, Sickle Cell; 3. *Nitric Oxide [therapeutic use]; 4. Oxygen; 5. Pain [drug therapy, etiology]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
1. *Antimalarials [adverse effects]; 2. *Artemisinins [adverse effects]; 3. Artesunate [therapeutic use]; 4. Bilirubin; 5. Drug Combinations; 6. *Malaria, Falciparum [drug therapy]; 7. Naphthyridines;
MESH terms:
Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta‐analysis
1. *Anemia [drug therapy, etiology]; 2. Erythropoiesis; 3. *Hematinics [therapeutic use]; 4. *Hypertension; 5. Iron [therapeutic use]; 6. *Neoplasms [complications]; 7. Network Meta-Analysis; 8. *Thrombocytopenia;
MESH terms:
Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents
1. Chronic Disease; 2. *Graft vs Host Disease [therapy]; 3. *Hematopoietic Stem Cell Transplantation [adverse effects]; 4. Methoxsalen; 5. *Photopheresis [adverse effects]; 6. Steroids;
MESH terms:
Indoor residual spraying for preventing malaria in communities using insecticide‐treated nets
1. *Insecticide-Treated Bednets; 2. *Insecticides; 3. *Malaria [prevention & control]; 4. Mosquito Control; 5. Mosquito Vectors; 6. Tanzania;
MESH terms:
Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease
1. *Albuminuria [drug therapy, etiology]; 2. *Anemia, Sickle Cell [complications, drug therapy]; 3. *Angiotensin-Converting Enzyme Inhibitors [therapeutic use]; 4. Angiotensins; 5. *Proteinuria [drug therapy, etiology]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Maternal and foetal outcomes following natural vaginal versus caesarean section (c‐section) delivery in women with bleeding disorders and carriers
1. *Blood Coagulation Disorders; 2. Cesarean Section; 3. Fetus; 4. *Labor, Obstetric; 5. *Pregnancy Complications, Hematologic;
MESH terms:
Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay‐Sachs disease
1. *Anemia, Sickle Cell [genetics]; 2. *Cystic Fibrosis [genetics]; 3. Risk Assessment; 4. *Tay-Sachs Disease [genetics]; 5. *Thalassemia;
MESH terms:
Recombinant growth hormone therapy for X‐linked hypophosphatemia in children
1. Body Height; 2. Cross-Over Studies; 3. *Familial Hypophosphatemic Rickets [drug therapy]; 4. Growth Hormone; 5. *Human Growth Hormone [therapeutic use];
MESH terms:
Mass drug administration for malaria
1. *Antimalarials [adverse effects]; 2. *Malaria [drug therapy, epidemiology]; 3. *Malaria, Falciparum; 4. Mass Drug Administration; 5. Parasitemia [drug therapy];
MESH terms:
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI
1. Enzyme Replacement Therapy; 2. *Mucopolysaccharidosis VI [drug therapy]; 3. *N-Acetylgalactosamine-4-Sulfatase; 4. Quality of Life; 5. Recombinant Proteins;
MESH terms:
Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
1. Cell- and Tissue-Based Therapy; 2. Immunotherapy, Adoptive; 3. *Lymphoma, Large B-Cell, Diffuse [therapy]; 4. Neoplasm Recurrence, Local; 5. Observational Studies as Topic; 6. *Receptors, Chimeric Antigen;
MESH terms:
Rituximab for eradicating inhibitors in people with acquired haemophilia A
1. *Hemophilia A [drug therapy]; 2. Hemorrhage; 3. *Hemostatics; 4. Rituximab [therapeutic use];
MESH terms:
Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B
1. Blood Coagulation Factors [*therapeutic use]; 2. Factor VIII [*therapeutic use]; 3. Hemarthrosis [*prevention & control]; 4. Hemophilia A [*complications]; 5. Hemophilia B [*complications]; 6. *Pharmaceutical Preparations;
MESH terms:
Intermittent preventive treatment for malaria in infants
1. Africa South of the Sahara; 2. Amodiaquine [therapeutic use]; 3. Antimalarials [*therapeutic use]; 4. Artemisinins [therapeutic use]; 5. Bias; 6. Confidence Intervals; 7. Disease Eradication; 8. Drug Combinations; 9. Endemic Diseases [*prevention & control]; 10. Hospitalization [statistics & numerical data]; 11. Malaria [*prevention & control]; 12. Parasitemia [drug therapy]; 13. Pyrimethamine [therapeutic use]; 14. Quinolines [therapeutic use]; 15. Randomized Controlled Trials as Topic; 16. Sulfadoxine [therapeutic use];
MESH terms:
Hematopoietic stem cell transplantation for people with β‐thalassaemia
1. beta-Thalassemia [*therapy]; 2. *Hematopoietic Stem Cell Transplantation;
MESH terms:
Disease‐modifying treatments for primary autoimmune haemolytic anaemia
1. Anemia, Hemolytic, Autoimmune [*drug therapy]; 2. Bias; 3. Confidence Intervals; 4. Drug Therapy, Combination [methods]; 5. Erythrocyte Transfusion; 6. Glucocorticoids [administration & dosage, *therapeutic use]; 7. Immunologic Factors [administration & dosage, *therapeutic use]; 8. Prednisolone [administration & dosage, *therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Rituximab [*therapeutic use];
MESH terms:
Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease
1. Age Factors; 2. Anemia, Sickle Cell [*complications, genetics]; 3. *Antibiotic Prophylaxis [adverse effects]; 4. beta-Thalassemia [complications]; 5. Bias; 6. Hemoglobin SC Disease [complications]; 7. Homozygote; 8. Incidence; 9. Medication Adherence; 10. Penicillins [adverse effects, *therapeutic use]; 11. Pneumococcal Infections [epidemiology, mortality, *prevention & control]; 12. Randomized Controlled Trials as Topic; 13. Streptococcus pneumoniae;
MESH terms:
Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria
1. Amodiaquine [therapeutic use]; 2. Antimalarials [*therapeutic use]; 3. Artemether, Lumefantrine Drug Combination [therapeutic use]; 4. Artemisinins [therapeutic use]; 5. Atovaquone [*therapeutic use]; 6. Cameroon; 7. Colombia; 8. Drug Combinations; 9. Ethiopia; 10. Malaria, Falciparum [*drug therapy]; 11. Mefloquine [therapeutic use]; 12. Proguanil [*therapeutic use]; 13. Randomized Controlled Trials as Topic; 14. Thailand; 15. Treatment Failure;
MESH terms:
Interventions for treating leg ulcers in people with sickle cell disease
1. *Anemia, Sickle Cell [complications, therapy]; 2. Bandages; 3. *Leg Ulcer [etiology, therapy]; 4. Quality of Life; 5. Wound Healing;
MESH terms:
Tyrosine supplementation for phenylketonuria
1. *Dietary Supplements; 2. Intelligence [drug effects]; 3. Neuropsychological Tests; 4. Phenylalanine [blood]; 5. Phenylketonurias [blood, diet therapy, *drug therapy]; 6. Placebos [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Tyrosine [blood, *therapeutic use];
MESH terms:
Paediatric formulations of artemisinin‐based combination therapies for treating uncomplicated malaria in children
1. Antimalarials [adverse effects, *therapeutic use]; 2. Artemether, Lumefantrine Drug Combination [adverse effects, *therapeutic use]; 3. Artemisinins [adverse effects, *therapeutic use]; 4. Bias; 5. Confidence Intervals; 6. Drug Combinations; 7. Malaria, Falciparum [*drug therapy]; 8. Quinolines [adverse effects, *therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Suspensions; 11. Tablets; 12. Treatment Failure; 13. Vomiting [chemically induced, epidemiology];
MESH terms:
Gene therapy for sickle cell disease
1. Anemia, Sickle Cell [genetics, *therapy]; 2. *Genetic Therapy;
MESH terms:
Phytomedicines (medicines derived from plants) for sickle cell disease
1. Amaranthaceae [chemistry]; 2. Anemia [chemically induced]; 3. Anemia, Sickle Cell [blood, *drug therapy]; 4. Antisickling Agents [adverse effects, *therapeutic use]; 5. Cajanus; 6. Clinical Trials, Phase II as Topic; 7. *Phytotherapy [adverse effects]; 8. Plant Extracts [adverse effects, *therapeutic use]; 9. Plant Roots [chemistry]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Rituximab for treating inhibitors in people with inherited severe hemophilia
1. Antibodies; 2. Factor IX [antagonists & inhibitors, *immunology]; 3. Factor VIII [antagonists & inhibitors, *immunology]; 4. Hemophilia A [blood, *drug therapy]; 5. Hemophilia B [blood, *drug therapy]; 6. Immunologic Factors [*therapeutic use]; 7. Rituximab [*therapeutic use];
MESH terms:
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease
1. Anemia, Sickle Cell [blood, *complications]; 2. Antisickling Agents [adverse effects, therapeutic use]; 3. Blood Transfusion; 4. Early Termination of Clinical Trials; 5. *Erythrocyte Transfusion [adverse effects]; 6. Hemoglobin, Sickle; 7. Hydroxyurea [adverse effects, therapeutic use]; 8. Iron Chelating Agents [therapeutic use]; 9. Phlebotomy [adverse effects]; 10. *Primary Prevention; 11. *Secondary Prevention; 12. Stroke [etiology, *prevention & control];
MESH terms:
Dietary interventions for phenylketonuria
1. Intelligence; 2. Phenylalanine [*administration & dosage, blood]; 3. Phenylketonurias [blood, *diet therapy]; 4. Randomized Controlled Trials as Topic; 5. Treatment Outcome; 6. Withholding Treatment;
MESH terms:
Interventions for mycosis fungoides
1. Acitretin [adverse effects, therapeutic use]; 2. Antineoplastic Agents [administration & dosage, adverse effects]; 3. Bexarotene [therapeutic use]; 4. Combined Modality Therapy [methods]; 5. Immunologic Factors [therapeutic use]; 6. Interferon-alpha [therapeutic use]; 7. Mycosis Fungoides [pathology, *therapy]; 8. Neoplasm Staging [methods]; 9. Photochemotherapy [methods]; 10. Photopheresis [methods]; 11. PUVA Therapy [methods]; 12. Randomized Controlled Trials as Topic; 13. Skin Neoplasms [pathology, *therapy];
MESH terms:
Hematopoietic stem cell transplantation for people with sickle cell disease
1. Anemia, Sickle Cell [*surgery]; 2. *Hematopoietic Stem Cell Transplantation;
MESH terms:
Preoperative blood transfusions for sickle cell disease
1. Acute Chest Syndrome [etiology]; 2. Adenoidectomy; 3. Anemia, Sickle Cell [blood, complications, *surgery]; 4. Blood Transfusion [*methods]; 5. Cholecystectomy [adverse effects]; 6. *Hemoglobin, Sickle; 7. Preoperative Care [*methods]; 8. Randomized Controlled Trials as Topic; 9. Tonsillectomy; 10. Transfusion Reaction;
MESH terms:
Interventions for treating intrahepatic cholestasis in people with sickle cell disease
1. Anemia, Sickle Cell [*complications]; 2. Cholestasis, Intrahepatic [etiology, *therapy];
MESH terms:
Growth hormone therapy for people with thalassaemia
1. beta-Thalassemia [*complications, genetics]; 2. Confidence Intervals; 3. Growth [*drug effects, physiology]; 4. Growth Disorders [*drug therapy, etiology]; 5. Homozygote; 6. Human Growth Hormone [*therapeutic use];
MESH terms:
Vitamin D supplementation for sickle cell disease
1. Administration, Oral; 2. Anemia, Sickle Cell [*blood, *complications]; 3. Bias; 4. Cholecalciferol [*administration & dosage, adverse effects]; 5. Pain [drug therapy]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Time Factors; 9. Vitamin D [*administration & dosage, adverse effects, *analogs & derivatives, blood]; 10. Vitamin D Deficiency [therapy];
MESH terms:
Gene therapy for haemophilia
1. *Genetic Therapy; 2. Hemophilia A [*therapy]; 3. Hemophilia B [*therapy];
MESH terms:
Interventions for preventing silent cerebral infarcts in people with sickle cell disease
1. Anemia, Sickle Cell [*complications, drug therapy]; 2. Antisickling Agents [adverse effects, *therapeutic use]; 3. Brain Infarction [etiology, *prevention & control]; 4. Cause of Death; 5. Cognition [physiology]; 6. *Erythrocyte Transfusion; 7. Hydroxyurea [adverse effects, *therapeutic use]; 8. *Phlebotomy [adverse effects]; 9. Primary Prevention [methods]; 10. Quality of Life; 11. Randomized Controlled Trials as Topic; 12. Secondary Prevention [methods]; 13. Stroke [prevention & control];
MESH terms:
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease
1. Analgesics [therapeutic use]; 2. Anemia, Sickle Cell [physiopathology]; 3. Chronic Pain [etiology, *therapy]; 4. Pain Management [*methods]; 5. Randomized Controlled Trials as Topic; 6. Transcutaneous Electric Nerve Stimulation [*methods];
MESH terms:
Early erythropoiesis‐stimulating agents in preterm or low birth weight infants
1. Anemia, Neonatal [blood, prevention & control]; 2. Enterocolitis, Necrotizing [blood, prevention & control]; 3. Erythropoiesis; 4. Erythropoietin [administration & dosage, blood]; 5. Hematinics [*administration & dosage]; 6. Infant, Low Birth Weight [*blood]; 7. Infant, Premature [*blood]; 8. Randomized Controlled Trials as Topic; 9. Retinopathy of Prematurity [blood, prevention & control];
MESH terms:
Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants
1. Anemia, Neonatal [blood, prevention & control]; 2. *Erythrocyte Transfusion; 3. Hematinics [administration & dosage, *therapeutic use]; 4. Infant, Low Birth Weight [*blood]; 5. Infant, Premature [*blood]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Blood transfusions for treating acute chest syndrome in people with sickle cell disease
1. Acute Chest Syndrome [etiology, mortality, *therapy]; 2. Anemia, Sickle Cell [*complications]; 3. *Blood Transfusion; 4. Randomized Controlled Trials as Topic; 5. Treatment Outcome;
MESH terms:
Intravenous iron therapy for non‐anaemic, iron‐deficient adults
1. *Iron Deficiencies; 2. Hemoglobins [*metabolism]; 3. Infusions, Intravenous; 4. Iron [*therapeutic use]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Treatment of dental complications in sickle cell disease
1. Anemia, Sickle Cell [*complications]; 2. Craniofacial Abnormalities [complications]; 3. Dental Care [*methods]; 4. Randomized Controlled Trials as Topic; 5. Tooth Diseases [*etiology, therapy];
MESH terms:
Treatment for avascular necrosis of bone in people with sickle cell disease
1. Anemia, Sickle Cell [*complications]; 2. Osteonecrosis [*etiology, *therapy]; 3. Physical Therapy Modalities; 4. Quality of Life; 5. Randomized Controlled Trials as Topic;
MESH terms:
Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non‐cardiac surgery or invasive procedures
1. Anticoagulants [adverse effects, *therapeutic use]; 2. Blood Component Transfusion [*methods]; 3. Hemorrhage [*prevention & control]; 4. Hemostatics [therapeutic use]; 5. Plasma; 6. Preoperative Care; 7. Randomized Controlled Trials as Topic; 8. *Surgical Procedures, Operative; 9. Thrombelastography;
MESH terms:
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis
1. Antibodies, Monoclonal [therapeutic use]; 2. Antineoplastic Agents [*therapeutic use]; 3. Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; 4. Bortezomib [therapeutic use]; 5. Lenalidomide [therapeutic use]; 6. Multiple Myeloma [*drug therapy]; 7. Network Meta-Analysis; 8. Randomized Controlled Trials as Topic; 9. Thalidomide [therapeutic use];
MESH terms:
Pharmacological interventions for painful sickle cell vaso‐occlusive crises in adults
1. Acute Pain [*drug therapy, *etiology]; 2. Analgesics [*therapeutic use]; 3. Analgesics, Opioid [therapeutic use]; 4. Anemia, Sickle Cell [*complications]; 5. Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; 6. Pain Management [methods]; 7. Pain Measurement; 8. Peripheral Vascular Diseases [drug therapy, etiology]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Statins for children with familial hypercholesterolemia
1. Cholesterol, LDL [blood]; 2. Hydroxymethylglutaryl-CoA Reductase Inhibitors [adverse effects, *therapeutic use]; 3. Hyperlipoproteinemia Type II [blood, *drug therapy, genetics]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease
1. Acute Chest Syndrome [etiology, *therapy]; 2. Anemia, Sickle Cell [*complications]; 3. Antisickling Agents [therapeutic use]; 4. Erythrocyte Transfusion [*methods]; 5. Hypertension, Pulmonary [etiology, *therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Antibiotics for treating osteomyelitis in people with sickle cell disease
1. Anemia, Sickle Cell [*complications]; 2. Anti-Bacterial Agents [*therapeutic use]; 3. Osteomyelitis [*drug therapy];
MESH terms:
Splenectomy for people with thalassaemia major or intermedia
1. beta-Thalassemia [*surgery]; 2. Blood Transfusion; 3. *Laparoscopy; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Splenectomy [*methods];
MESH terms:
Magnesium for treating sickle cell disease
1. Anemia, Sickle Cell [blood, *drug therapy]; 2. Antisickling Agents [*therapeutic use]; 3. Hydroxyurea [therapeutic use]; 4. Magnesium [blood, *therapeutic use]; 5. Magnesium Sulfate [therapeutic use]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions
1. Antifibrinolytic Agents [*therapeutic use]; 2. Hemophilia A [*complications, drug therapy]; 3. Minor Surgical Procedures [adverse effects]; 4. Oral Hemorrhage [*prevention & control]; 5. Postoperative Hemorrhage [prevention & control]; 6. Surgery, Oral; 7. Tooth Extraction [adverse effects]; 8. von Willebrand Diseases [*complications];
MESH terms:
Hydroxyurea (hydroxycarbamide) for transfusion‐dependent β‐thalassaemia
1. beta-Thalassemia [*drug therapy]; 2. Blood Transfusion [*statistics & numerical data]; 3. Hematinics [adverse effects, *therapeutic use]; 4. Hydroxyurea [adverse effects, *therapeutic use];
MESH terms:
Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders
1. Blood Coagulation Disorders [congenital, *drug therapy, *prevention & control]; 2. Deamino Arginine Vasopressin [*therapeutic use]; 3. Hemostatics [*therapeutic use]; 4. Pregnancy Complications, Hematologic [*drug therapy, *prevention & control];
MESH terms:
Aerobic physical exercise for adult patients with haematological malignancies
1. *Exercise; 2. Exercise Tolerance; 3. Feasibility Studies; 4. Hematologic Neoplasms [complications, mortality, *rehabilitation]; 5. Physical Conditioning, Human; 6. Qigong; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Resistance Training; 10. Tai Ji; 11. Yoga;
MESH terms:
Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition
1. Acute Disease; 2. beta-Thalassemia [*therapy]; 3. Chronic Disease; 4. Graft vs Host Disease [epidemiology, *therapy]; 5. Hematologic Neoplasms [mortality, *therapy]; 6. Hematopoietic Stem Cell Transplantation [*adverse effects]; 7. Incidence; 8. *Mesenchymal Stem Cell Transplantation [mortality]; 9. Randomized Controlled Trials as Topic; 10. Recurrence;
MESH terms:
Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer
1. Anti-Bacterial Agents [*therapeutic use]; 2. Drug Resistance, Bacterial; 3. Febrile Neutropenia [*drug therapy, mortality]; 4. Neoplasms [*complications]; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome; 7. *Withholding Treatment;
MESH terms:
Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia
1. Blood Coagulation Factors [*therapeutic use]; 2. Cause of Death; 3. Factor XIII [*therapeutic use]; 4. Fibrinogen [*therapeutic use]; 5. Hemorrhage [mortality, prevention & control, *therapy]; 6. Hemostatics [*therapeutic use]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Vaccines for preventing invasive salmonella infections in people with sickle cell disease
1. Anemia, Sickle Cell [*complications]; 2. Salmonella Infections [*prevention & control]; 3. Salmonella Vaccines [*administration & dosage];
MESH terms:
Insecticide‐treated nets for preventing malaria
1. Cause of Death; 2. Insecticide Resistance; 3. *Insecticide-Treated Bednets; 4. Malaria [mortality, *prevention & control]; 5. Malaria, Falciparum [mortality, prevention & control]; 6. Malaria, Vivax [mortality, prevention & control]; 7. Mosquito Control [*methods]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Drugs for preventing red blood cell dehydration in people with sickle cell disease
1. Acetamides [*therapeutic use]; 2. Anemia, Sickle Cell [*blood, complications]; 3. Antisickling Agents [*therapeutic use]; 4. Clinical Trials, Phase II as Topic; 5. Clinical Trials, Phase III as Topic; 6. Dehydration [*prevention & control]; 7. Early Termination of Clinical Trials; 8. Erythrocyte Aging [drug effects]; 9. Erythrocytes [*drug effects]; 10. Piracetam [therapeutic use]; 11. Quality of Life; 12. Randomized Controlled Trials as Topic; 13. Trityl Compounds [*therapeutic use]; 14. Zinc Sulfate [*therapeutic use];
MESH terms:
Prophylactic platelet transfusions prior to surgery for people with a low platelet count
1. Benzoates [therapeutic use]; 2. Deamino Arginine Vasopressin [therapeutic use]; 3. Hemostatics [therapeutic use]; 4. Hydrazines [therapeutic use]; 5. Plasma; 6. Platelet Transfusion [*methods]; 7. Postoperative Care [methods]; 8. Postoperative Hemorrhage [*prevention & control]; 9. Pyrazoles [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Receptors, Fc [therapeutic use]; 12. Recombinant Fusion Proteins [therapeutic use]; 13. Thrombocytopenia [complications, *therapy]; 14. Thrombopoietin [therapeutic use];
MESH terms:
Conjugate Haemophilus influenzae type b vaccines for sickle cell disease
1. Anemia, Sickle Cell [*complications]; 2. Bacterial Capsules [immunology]; 3. Haemophilus Infections [*prevention & control]; 4. Haemophilus influenzae type b [*immunology]; 5. Haemophilus Vaccines [*administration & dosage, immunology]; 6. Vaccines, Conjugate [administration & dosage, immunology];
MESH terms:
Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (non‐APL))
1. Antineoplastic Agents [adverse effects, *therapeutic use]; 2. Decitabine [adverse effects, therapeutic use]; 3. Diarrhea [chemically induced]; 4. Disease Progression; 5. Heart [drug effects]; 6. Infections [chemically induced]; 7. Leukemia, Myeloid, Acute [*drug therapy, mortality]; 8. Nausea [chemically induced]; 9. Recurrence; 10. Tretinoin [adverse effects, *therapeutic use]; 11. Vomiting [chemically induced];
MESH terms:
Comparison of a therapeutic‐only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders
1. Myelodysplastic Syndromes [congenital, *therapy]; 2. Platelet Transfusion [*methods];
MESH terms:
Folate supplementation in people with sickle cell disease
1. Anemia, Sickle Cell [blood, *drug therapy]; 2. Double-Blind Method; 3. Erythrocyte Indices; 4. Folic Acid [*administration & dosage, blood]; 5. Growth; 6. Hematinics [*administration & dosage];
MESH terms:
Mosquito repellents for malaria prevention
1. *Culicidae; 2. *Insect Repellents; 3. *Protective Clothing; 4. Incidence; 5. Insecticide‐Treated Bednets; 6. Malaria, Falciparum [epidemiology, *prevention & control]; 7. Malaria, Vivax [epidemiology, *prevention & control]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Bisphosphonates in multiple myeloma: an updated network meta‐analysis
1. Antineoplastic Agents [*therapeutic use]; 2. Bone Density Conservation Agents [*therapeutic use]; 3. Bone Diseases [*drug therapy, mortality]; 4. Clodronic Acid [therapeutic use]; 5. Diphosphonates [*therapeutic use]; 6. Disease‐Free Survival; 7. Etidronic Acid [therapeutic use]; 8. Fractures, Bone [epidemiology, prevention & control]; 9. Imidazoles [therapeutic use]; 10. Multiple Myeloma [complications, *drug therapy, mortality]; 11. Pamidronate; 12. Randomized Controlled Trials as Topic; 13. Spinal Fractures [epidemiology, prevention & control]; 14. Zoledronic Acid;
MESH terms:
Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in patients with solid tumours
1. Antineoplastic Agents [*adverse effects]; 2. Benzoates [*administration & dosage]; 3. Hydrazines [*administration & dosage]; 4. Neoplasms [drug therapy]; 5. Pyrazoles [*administration & dosage]; 6. Randomized Controlled Trials as Topic; 7. Receptors, Fc [*administration & dosage]; 8. Receptors, Thrombopoietin [*agonists]; 9. Recombinant Fusion Proteins [*administration & dosage]; 10. Thrombocytopenia [chemically induced, *drug therapy, mortality, *prevention & control]; 11. Thrombopoietin [*administration & dosage];
MESH terms:
Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease
1. Acute Disease; 2. Anemia, Sickle Cell [*complications]; 3. *Blood Transfusion; 4. *Conservative Treatment; 5. Recurrence; 6. Secondary Prevention; 7. *Splenectomy; 8. Splenic Diseases [surgery, *therapy];
MESH terms:
Hematopoietic stem cell transplantation for Gaucher disease
1. Gaucher Disease [*surgery]; 2. *Hematopoietic Stem Cell Transplantation [mortality];
MESH terms:
Prophylactic intravenous calcium therapy for exchange blood transfusion in the newborn
1. Administration, Intravenous; 2. Apnea [etiology]; 3. Calcium [*administration & dosage, adverse effects, blood]; 4. Exchange Transfusion, Whole Blood [*adverse effects]; 5. Heart Arrest [etiology]; 6. Hypocalcemia [etiology, *prevention & control]; 7. Hypoglycemia [etiology];
MESH terms:
Thrombopoietin mimetics for patients with myelodysplastic syndromes
1. Azacitidine [analogs & derivatives, therapeutic use]; 2. Benzoates [*therapeutic use]; 3. Blood Transfusion [statistics & numerical data]; 4. Decitabine; 5. Hemorrhage [chemically induced]; 6. Hydrazines [*therapeutic use]; 7. Lenalidomide; 8. Leukemia, Myeloid, Acute [etiology]; 9. Myelodysplastic Syndromes [*complications, mortality]; 10. Pyrazoles [*therapeutic use]; 11. Quality of Life; 12. Randomized Controlled Trials as Topic; 13. Receptors, Fc [*therapeutic use]; 14. Recombinant Fusion Proteins [*therapeutic use]; 15. Thalidomide [analogs & derivatives, therapeutic use]; 16. Thrombocytopenia [*drug therapy, etiology]; 17. Thrombopoietin [*therapeutic use];
MESH terms:
Plasma transfusions prior to lumbar punctures and epidural catheters for people with abnormal coagulation
1. *Blood Transfusion; 2. Blood Coagulation Disorders [*complications]; 3. Hemorrhage [*prevention & control]; 4. Spinal Puncture [*adverse effects];
MESH terms:
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
1. Coagulants [*therapeutic use]; 2. Factor VIIa [*therapeutic use]; 3. Hemarthrosis [*prevention & control]; 4. Hemophilia A [complications, *drug therapy]; 5. Hemophilia B [complications, *drug therapy]; 6. Prothrombin [*therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Recombinant Proteins [therapeutic use];
MESH terms:
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression‐free survival: individual participant data analysis
1. Antineoplastic Agents [administration & dosage]; 2. Antineoplastic Combined Chemotherapy Protocols [administration & dosage, adverse effects, standards]; 3. Bleomycin [administration & dosage, adverse effects]; 4. Chemoradiotherapy [methods, standards]; 5. Dacarbazine [administration & dosage, adverse effects]; 6. Disease-Free Survival; 7. Doxorubicin [administration & dosage, adverse effects]; 8. Hodgkin Disease [*drug therapy, *radiotherapy]; 9. Leukemia, Radiation-Induced [mortality, prevention & control]; 10. Myelodysplastic Syndromes [etiology]; 11. Neoplasms, Second Primary [etiology, mortality, *prevention & control]; 12. Radiotherapy [adverse effects, standards]; 13. Radiotherapy Dosage; 14. Randomized Controlled Trials as Topic; 15. Vinblastine [administration & dosage, adverse effects];
MESH terms:
Deferasirox for managing iron overload in people with thalassaemia
1. Administration, Oral; 2. Benzoates [administration & dosage, adverse effects, *therapeutic use]; 3. Clinical Trials, Phase II as Topic; 4. Clinical Trials, Phase III as Topic; 5. Deferasirox; 6. Deferiprone; 7. Deferoxamine [administration & dosage, therapeutic use]; 8. Erythrocyte Transfusion [adverse effects]; 9. Ferritins [blood]; 10. Iron Chelating Agents [administration & dosage, adverse effects, *therapeutic use]; 11. Iron Overload [blood, *drug therapy, etiology]; 12. Patient Satisfaction; 13. Pyridones [administration & dosage, therapeutic use]; 14. Randomized Controlled Trials as Topic; 15. Thalassemia [*complications, mortality, therapy]; 16. Triazoles [administration & dosage, adverse effects, *therapeutic use];
MESH terms:
Fluid replacement therapy for acute episodes of pain in people with sickle cell disease
1. Acute Pain [etiology, *therapy]; 2. Anemia, Sickle Cell [complications, *therapy]; 3. *Fluid Therapy; 4. Pain Management [*methods];
MESH terms:
Pathogen‐reduced platelets for the prevention of bleeding
1. Antisepsis [*methods]; 2. Blood Platelets [*microbiology]; 3. Disease Transmission, Infectious [*prevention & control]; 4. Furocoumarins; 5. Hemorrhage [epidemiology, *prevention & control]; 6. Photosensitizing Agents; 7. *Platelet Transfusion; 8. Randomized Controlled Trials as Topic; 9. Riboflavin; 10. Thrombocytopenia [*therapy]; 11. Ultraviolet Rays;
MESH terms:
Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma
1. Antineoplastic Combined Chemotherapy Protocols [administration & dosage, adverse effects, *therapeutic use]; 2. Bleomycin [administration & dosage, adverse effects]; 3. Cyclophosphamide [administration & dosage, adverse effects]; 4. Dacarbazine [administration & dosage, adverse effects]; 5. Disease Progression; 6. Doxorubicin [administration & dosage, adverse effects]; 7. Etoposide [administration & dosage, adverse effects]; 8. Hodgkin Disease [*drug therapy, mortality, pathology]; 9. Prednisone [administration & dosage, adverse effects]; 10. Procarbazine [administration & dosage, adverse effects]; 11. Randomized Controlled Trials as Topic; 12. Vinblastine [administration & dosage, adverse effects]; 13. Vincristine [administration & dosage, adverse effects];
MESH terms:
Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma
1. Chemoradiotherapy; 2. Combined Modality Therapy [methods]; 3. Disease Progression; 4. Heart Diseases [mortality]; 5. Hodgkin Disease [*drug therapy, mortality, pathology, *radiotherapy]; 6. Infections [mortality]; 7. Neoplasms, Second Primary [mortality]; 8. Randomized Controlled Trials as Topic; 9. Recurrence; 10. Survival Analysis;
MESH terms:
Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in postoperative patients
1. Anticoagulants [*administration & dosage, adverse effects]; 2. Heparin [*administration & dosage, adverse effects]; 3. Heparin, Low-Molecular-Weight [*administration & dosage, adverse effects]; 4. Numbers Needed To Treat; 5. Postoperative Complications [chemically induced, *prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Surgical Procedures, Operative [statistics & numerical data]; 8. Thrombocytopenia [chemically induced, complications, *prevention & control]; 9. Thrombosis [etiology, *prevention & control]; 10. Venous Thrombosis [etiology, prevention & control];
MESH terms:
Exercise for haemophilia
1. Exercise Therapy [*methods]; 2. Hemarthrosis [rehabilitation]; 3. Hemophilia A [*rehabilitation]; 4. Hemophilia B [*rehabilitation]; 5. Hydrotherapy; 6. Muscle Strength; 7. Muscle Stretching Exercises; 8. Pain [rehabilitation]; 9. Pain Measurement; 10. Randomized Controlled Trials as Topic; 11. Range of Motion, Articular; 12. Resistance Training;
MESH terms:
Antibiotics for treating community‐acquired pneumonia in people with sickle cell disease
1. Acute Disease; 2. Anemia, Sickle Cell [*complications]; 3. Anti-Bacterial Agents [*therapeutic use]; 4. Community-Acquired Infections [drug therapy]; 5. Pneumonia, Bacterial [*drug therapy];
MESH terms:
Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias
1. beta-Thalassemia [blood, *drug therapy]; 2. Blood Transfusion [*statistics & numerical data]; 3. Hematinics [*administration & dosage]; 4. Hemoglobin A [analysis]; 5. Hydroxyurea [*administration & dosage]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta‐analysis and systematic review
1. Benzoates [*therapeutic use]; 2. Bone Marrow Diseases [*complications]; 3. Chronic Disease; 4. Deamino Arginine Vasopressin [*therapeutic use]; 5. Hemorrhage [etiology, *prevention & control]; 6. Hemostatics [*therapeutic use]; 7. Hydrazines [*therapeutic use]; 8. Platelet Transfusion; 9. Pyrazoles [*therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Receptors, Fc [*therapeutic use]; 12. Recombinant Fusion Proteins [*therapeutic use]; 13. Thrombocytopenia [*complications]; 14. Thrombopoietin [*therapeutic use]; 15. Tranexamic Acid [*therapeutic use];
MESH terms:
Bisphosphonate therapy for osteogenesis imperfecta
1. Administration, Oral; 2. Bone Density [drug effects]; 3. Bone Density Conservation Agents [administration & dosage, *therapeutic use]; 4. Diphosphonates [administration & dosage, *therapeutic use]; 5. Fractures, Bone [*prevention & control]; 6. Injections, Intravenous; 7. Osteogenesis Imperfecta [*drug therapy]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications
1. Anemia, Sickle Cell [*complications]; 2. Caregivers [*education]; 3. *Health Knowledge, Attitudes, Practice; 4. *Patient Education as Topic; 5. Randomized Controlled Trials as Topic;
MESH terms:
Bortezomib for the treatment of multiple myeloma
1. Antineoplastic Agents [*therapeutic use]; 2. Bortezomib [*therapeutic use]; 3. Multiple Myeloma [*drug therapy]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders
1. Aminocaproic Acid [*therapeutic use]; 2. Antifibrinolytic Agents [*therapeutic use]; 3. Erythrocyte Transfusion [statistics & numerical data]; 4. Hematologic Diseases [*complications, drug therapy]; 5. Hemorrhage [etiology, *prevention & control]; 6. Lysine [analogs & derivatives]; 7. Platelet Transfusion [adverse effects]; 8. Thrombocytopenia [etiology, therapy]; 9. Thromboembolism; 10. Tranexamic Acid [*therapeutic use];
MESH terms:
Subsidising artemisinin‐based combination therapy in the private retail sector
1. Africa, Eastern; 2. Antimalarials [*economics, *supply & distribution, therapeutic use]; 3. Artemisinins [*economics, *supply & distribution, therapeutic use]; 4. *Drug Costs; 5. Financial Support; 6. Malaria [*drug therapy]; 7. Private Sector [*economics]; 8. Program Evaluation; 9. Randomized Controlled Trials as Topic;
MESH terms:
Oral iron supplements for children in malaria‐endemic areas
1. Anemia, Iron-Deficiency [etiology, *prevention & control]; 2. Antimalarials [administration & dosage]; 3. Dietary Supplements [adverse effects]; 4. *Endemic Diseases; 5. Folic Acid [adverse effects]; 6. Iron [*administration & dosage, adverse effects]; 7. Malaria [chemically induced, *complications]; 8. Parasitemia [chemically induced, complications]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes
1. Erythropoietin [therapeutic use]; 2. Granulocyte-Macrophage Colony-Stimulating Factor [*therapeutic use]; 3. Macrophage Colony-Stimulating Factor [*therapeutic use]; 4. Myelodysplastic Syndromes [*drug therapy]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Piracetam for reducing the incidence of painful sickle cell disease crises
1. Anemia, Sickle Cell [complications, *drug therapy]; 2. Antisickling Agents [*therapeutic use]; 3. Pain [*drug therapy]; 4. Piracetam [*therapeutic use]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Meditation for adults with haematological malignancies
1. Acute Disease; 2. Depression [therapy]; 3. Hematologic Neoplasms [*psychology]; 4. Leukemia [psychology]; 5. Meditation [*psychology]; 6. Randomized Controlled Trials as Topic;